Bio Light files for stock offering

By SHARON WROBEL
April 17, 2006 06:45

Bio Light, which increased its market value to $15m. since floatation, also reported developments at three of its four subsidiaries.




Bio Light Israeli Life Sciences Investments Ltd., which went public in December 2005 at a value of $10 million, announced on Sunday it was planning a second offering on the Tel Aviv Stock Exchange. Bio Light, which increased its market value to $15m. since floatation, also reported developments at three of its four subsidiaries. Obcure Ltd., which has discovered a treatment for obesity, has obtained US Food and Drug Administration approval to bypass Phase I safety trials and jump directly to Phase II clinical trials; Allergica Ltd., which is developing an allergy treatment, has hired Yaffa Beck as chairperson; and Zetiq Technologies Ltd. will launch its first preparations for identifying cancerous cells in a few months.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS

Israel Weather
  • 6 - 13
    Beer Sheva
    13 - 15
    Tel Aviv - Yafo
  • 6 - 7
    Jerusalem
    11 - 12
    Haifa
  • 9 - 17
    Elat
    10 - 15
    Tiberias